

- Parrotfish poisoning, 2742
 Parrot's pseudoparalysis, 836
 Parsonage-Turner syndrome, 2692
 Pars planitis, 200
 Partial liquid ventilation, 1738–1739, 1742
 Partial response, to chemotherapy, 103e-5
 Partner notification, 883
 Parulis, 237
 PARV4/5 viral sequences, 1197
 Parvovirus(es), 214e-2t, 214e-3f, 214e-4, 1195
 Parvovirus B19 infections, **1195**
 aplastic anemia and, 664
 clinical features of, 1195f, 1196
 diagnosis of, 1196–1197, 1196t
 epidemiology of, 1195
 erythema infectiosum. *See* Erythema infectiosum
 hydrops fetalis. *See* Hydrops fetalis
 myocarditis, 1560
 pathogenesis of, 1195–1196, 1195f
 in pregnancy, 50, 1196
 prevention of, 1197
 pure red cell aplasia, 668, 668f, 1196. *See also* Pure red cell aplasia
 transfusion-transmitted, 138e-6
 in transplant recipient, 923
 treatment of, 669, 1197
 Parvus et tardus pulse, 51e-3, 1448
 Pasireotide, 567, 2272–2273
 Passive euthanasia, 67t
 Passive transport, 332e-6
 Pasteur effect, 247
Pasteurella spp. infections
 in cat-bite wound, 167e-1, 183e-3, 830
 cellulitis, 830
 clinical features of, 183e-3, 834
 in dog-bite wound, 167e-1, 183e-3
 treatment of, 167e-3, 167e-3t, 183e-2t, 183e-3, 830
 Pastia's lines, 134, 966, 966f
 Patch (skin lesion), 339t
 Patched gene, 387
 Patch testing, 344
 Patellar tendinitis, 2220–2221
 Patent ductus arteriosus (PDA)
 clinical features of, 1523, 1524f
 heart sounds/murmur in, 1449
 location of, 1521f, 1524f
 pathogenesis of, 1523
 treatment of, 1523
 Patent foramen ovale, 296e-4, 476e-3, 2566t
 Paternal age, Marfan syndrome and, 433, 438
 Paterson-Kelly syndrome, 532
 Pathogen-associated molecular patterns (PAMPs), 145e-5, 145e-8f, 372e-2, 377e-1, 1747
 Patient
 expectations of, 6–7
 hospital experience of, 5
 Internet use by, 6
 principles of patient care, 3–4
 Patient autonomy, 17e-2
 Patient-centeredness, 16e-6
 Patient-controlled analgesia, 92
 Patient Health Questionnaire-2 (PHQ-2)
 Depression Screen, 471e-5t
 Patient-physician relationship. *See* Physician-patient relationship
 Patient satisfaction, 16e-4–5
 Patient-ventilator synchrony, 1743
 Pattern recognition, 18–19
 Pattern-recognition molecules (collectins), 145e-5
 Pattern recognition receptors (PRRs). *See also* Toll-like receptors (TLRs)
 in adaptive immune response modulation, 372e-6t
 in autoimmunity, 377e-1–2
 definition of, 372e-2
 in innate immune system, 372e-2, 372e-4, 372e-4t
 ligands of, 372e-5t
 signaling pathways of, 372e-5f
 PAX3 gene mutations, 101e-3t, 359, 431t
 PAX7 gene mutations, 101e-3t
 PAX8 gene mutations, 2283, 2284t, 2304, 2305t
 Pay-for-performance system, 12e-4
 Pazopanib
 action and targets of, 102e-17, 102e-18t, 103e-19
 adverse effects of, 102e-18t, 103e-26
 for renal cell carcinoma, 579
 for soft tissue sarcoma, 119e-2
 P blood group system, 138e-2
 PC-1 gene mutations, 415e-4t, 2364t
 PCI. *See* Percutaneous coronary interventions (PCI)
 PCNSL. *See* Primary central nervous system lymphoma (PCNSL)
 PCOS. *See* Polycystic ovarian syndrome (PCOS)
 PCP. *See* Phencyclidine (PCP); *Pneumocystis pneumonia* (PCP)
 PC-PTSD (Primary Care PTSD) Screen, 471e-4
 PCR. *See* Polymerase chain reaction (PCR)
 PCSK9 deficiency, 2445
 PCSK9 inhibitors, 2442
 PCSK9 mutations, 2442, 2445
 PCT (procalcitonin), 806
 PCV (pressure-control ventilation), 1742. *See also* Mechanical ventilation
 PD. *See* Parkinson's disease (PD)
 PD-1 antibodies, 498, 499, 499f, 521
 PDA. *See* Patent ductus arteriosus (PDA)
 PDC (pyruvate dehydrogenase complex), 372e-24t, 2060
 PDD (Parkinson's disease dementia), 171, 2605–2606
 PDGF. *See* Platelet-derived growth factor (PDGF)
 PDGFR gene mutations, 135e-7, 135e-7t
 PDGFR-mutated eosinophilia, 135e-8
 PDK (pyruvate dehydrogenase kinase), 102e-13
 PD-L1, 103e-21, 103e-22f
 PE. *See* Pulmonary embolism (PE)
 Peak oxygen consumption, 73, 74f
 Pearson's syndrome, 85e-6, 85e-6t
 Peau d'orange skin, 967, 1654
 Pectoriloquy, 1662
 Pectus carinatum (pigeon chest), 1443, 2512
 Pectus excavatum (funnel chest), 1443, 2512
 Pedal edema, 1662
 Pediculiasis, 2745–2746
 Pediculosis, 2746
Pediculus capitatus (head lice), 2745–2746, 2746f
Pediculus humanus (body lice), 1146, 2745–2746. *See also* Epidemic (louse-borne) typhus
 Pedigree analysis
 in family history, 443
 in genetic counseling, 446, 447f
 in Mendelian disorders, 437–438, 438f
 in mitochondrial DNA diseases, 85e-1, 85e-2f
 standard symbols for, 438f
 Peduncular hallucinosis, 2575
 PEEP (positive end-expiratory pressure), 1738. *See also* Mechanical ventilation
 Pefloxacin, 379
 PEG-ADA, 91e-2
 Pegfilgrastim, 103e-24, 103e-24t
 PEG IFN- α 2a. *See* Pegylated interferon- α 2a (PEG IFN- α 2a)
 PEG IFN- α 2b. *See* Pegylated interferon- α 2b (PEG IFN- α 2b)
 Pegloticase, 2235
 Pegvisomant, 2271
 Pegylated interferon- α 2a (PEG IFN- α 2a)
 for chronic HBV infection, 215e-4t, 215e-10, 2035–2036, 2037t, 2040t
 for chronic HCV infection, 215e-4t, 2043–2044, 2043t, 2045–2046t, 2048
 for chronic HDV infection, 215e-5t, 2040
 Pegylated interferon- α 2b (PEG IFN- α 2b)
 adverse effects of, 498, 2060
 for chronic HBV infection, 2035–2036, 2037t, 2038f, 2039, 2040t
 for chronic HCV infection, 215e-4t, 2043–2044, 2043t, 2045–2046t, 2048
 with ribavirin, 215e-4t, 215e-10, 2043–2044
 for chronic HDV infection, 215e-5t, 215e-10, 2040
 for melanoma, 498
 PELD system, in liver transplantation, 1995
 Pel-Ebstein fever, 126, 708
 Pelger-Huet anomaly, 81e-6f, 415, 415f
 Peliosis hepatitis, 2027
 Pelizaeus-Merzbacher disease, 2636
 Pellagra
 clinical features of, 96e-1t, 96e-4, 360, 463t, 2607, 2690
 “gauntlet” of, 436e-1f
 global considerations in, 2690
 vs. Hartnup disease, 435e-2
 risk factors for, 96e-4
 treatment of, 96e-4, 2690
 Pelvic abscess, 1099
 Pelvic floor dysfunction, 273–274
 Pelvic floor relaxation, 60e-3
 Pelvic floor retraining, 274
 Pelvic fractures, 2489
 Pelvic inflammatory disease (PID), **876**
 abdominal pain in, 103, 106
 anaerobic, 1099
 C. trachomatis, 1169
 clinical features of, 877
 diagnosis of, 877–878
 epidemiology of, 877
 etiology of, 870t, 877
 follow-up for, 879
 M. hominis, 1165
 pelvic pain in, 338, 338t
 prevention of, 879
 prognosis of, 879
 treatment of, 878–879, 878t
 Pelvic muscle exercises (Kegel exercises), 81
 Pelvic pain, **337**
 acute, 338
 approach to the patient, 338
 in cervical cancer, 595
 chronic, 338
 etiology of, 337–338, 338t
 in interstitial cystitis/bladder pain syndrome, 60e-1–2
 in pelvic inflammatory disease. *See* Pelvic inflammatory disease (PID)
 Pelvic thrombophlebitis, septic, 50
 Pemberton's sign, 2301, 2302
 Pembrolizumab, 102e-5t, 103e-21t, 103e-22
 Pemetrexed
 action of, 103e-14
 adverse effects of, 103e-11t, 103e-14
 for lung cancer, 520, 520t, 521
 for ovarian cancer, 594
 Pemoline, 63
 Pemphigoid
 bullous, **372**
 clinical features of, 76e-15f, 370t, 372, 372d
 histology of, 370t, 372
 immunopathology of, 370t, 372, 372e-24t
 treatment of, 372
 esophageal involvement/dysphagia in, 257
 gestational, 361t, 370t, 372–373
 mucous membrane, 237, 239t, 370t, 372e-24t, 374
 Pemphigus
 drug-induced, 379
 paraneoplastic, 361, 361t, 370t, **372**
 Pemphigus foliaceus, **371**
 clinical features of, 370t, 371
 drug-induced, 371–372
 histology of, 370t
 immunopathology of, 370t, 371, 372e-24t
 treatment of, 372
 Pemphigus vulgaris, **370**
 clinical features of, 76e-15f, 370, 370t, 371f
 diagnosis of, 371
 histology of, 370t
 HLA gene association with, 373e-7, 373e-8t
 immunopathology of, 370–371, 370t, 372e-24t, 377e-4